AstraZeneca
AstraZeneca
From Wikipedia, the free encyclopedia
Jump to: navigation, search
 |
|
| Type | Public limited company (LSE: AZN, NASDAQ: AZN, OMX: AZN) |
|---|---|
| Industry | Pharmaceutical |
| Founded | 6 April 1999 by merger |
| Headquarters | London, United Kingdom |
| Key people | Louis Schweitzer, Chairman David R. Brennan, Chief Executive Officer[1] |
| Products | Pharmaceutical products for humans |
| Revenue | $32,804 million (2009)[2] |
| Operating income | $11,543 million (2009)[2] |
| Net income | $7,544 million (2009)[2] |
| Total assets | ▼ US$46.8 Billion (FY 2009)[3] |
| Total equity | ▲ US$15.9 Billion (FY 2009)[3] |
| Employees | 62,000 (2010)[4] |
| Website | astrazeneca.com |
AstraZeneca plc[5] (LSE: AZN, NYSE: AZN, OMX: AZN) is a global pharmaceutical and biologicscompany headquartered in London, United Kingdom. It is the world’s seventh largest pharmaceutical company measured by revenues and has operations in over 100 countries.[6][7] It has a portfolio of products for major disease areas including cancer, cardiovascular, gastrointestinal, infection, neuroscience, respiratoryinflammation.[4] and
Its primary listing is on the London Stock Exchange and it is a constituent of the FTSE 100 Index. It has secondary listings on the New York Stock Exchange and the OMX exchange.
Contents
[show]
No comments yet.
Powers and Principalities 
Leave a comment